Trial · NCT05819398
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 8 | Placebo | -21.5 | Standard Error 7.7 | Percentage change | |
| Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 8 | Spesolimab low dose group | -41.9 | Standard Error 7.8 | Percentage change | |
| Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 8 | Spesolimab medium dose group | -39.3 | Standard Error 7.9 | Percentage change | |
| Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 8 | Spesolimab high dose group | -25.8 | Standard Error 7.9 | Percentage change | |
| Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 16 | Placebo | -14.0 | Standard Error 10.6 | Percentage change | |
| Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 16 | Spesolimab low dose group | -23.5 | Standard Error 10.7 | Percentage change | |
| Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 16 | Spesolimab medium dose group | -36.2 | Standard Error 10.8 | Percentage change | |
| Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 16 | Spesolimab high dose group | -22.7 | Standard Error 11.2 | Percentage change | |
| Part 1 - Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 8 | Placebo | -13.5 | Standard Error 2.5 | Units on a scale | |
| Part 1 - Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 8 | Spesolimab low dose group | -11.1 | Standard Error 2.5 | Units on a scale | |
| Part 1 - Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 8 | Spesolimab medium dose group | -14.1 | Standard Error 2.5 | Units on a scale | |
| Part 1 - Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 8 | Spesolimab high dose group | -10.5 | Standard Error 2.5 | Units on a scale | |
| Part 1 - Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 16 | Placebo | -11.8 | Standard Error 3.8 | Units on a scale | |
| Part 1 - Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 16 | Spesolimab low dose group | -7.2 | Standard Error 3.9 | Units on a scale | |
| Part 1 - Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 16 | Spesolimab medium dose group | -17.0 | Standard Error 3.9 | Units on a scale | |
| Part 1 - Absolute Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) Value at Week 16 | Spesolimab high dose group | -4.2 | Standard Error 4.0 | Units on a scale | |
| Part 1 - Occurrence of Treatment Emergent Adverse Events (TEAEs) | Placebo | 44 | Participants | ||
| Part 1 - Occurrence of Treatment Emergent Adverse Events (TEAEs) | Spesolimab low dose group | 47 | Participants | ||
| Part 1 - Occurrence of Treatment Emergent Adverse Events (TEAEs) | Spesolimab medium dose group | 51 | Participants | ||
| Part 1 - Occurrence of Treatment Emergent Adverse Events (TEAEs) | Spesolimab high dose group | 47 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05819398/results